NCT00987753View on ClinicalTrials.gov

Study Evaluating the Safety and Tolerability of L-377202

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

September 30, 2000

Study Completion Date

November 30, 2001

Conditions
Hormone Refractory Prostate CancerProstate Cancer
Interventions
DRUG

L-377202

For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT00987753 - Study Evaluating the Safety and Tolerability of L-377202 | Biotech Hunter | Biotech Hunter